TCG Crossover
Crossover fundActively deployingPalo Alto · Seed–Late Stage · 25 people tracked
Also known as TCG CROSSOVER MANAGEMENT, LLC
Investment thesis
TCG Crossover is a science-driven crossover investment firm dedicated to advancing disruptive medicines. It focuses on companies developing innovative therapeutics and life-science breakthroughs.
Source: firm website, verified Aug 25, 2026.
Team · 25 people
from the firm's website & public directories
What they invest in
from 23 of 30 portfolio companiesBiotech ×22Healthtech ×14Medical Devices ×10Digital Health ×6Deep Tech ×4AI & Machine Learning ×3Consumer ×1
HQs:United States×12
Investments · 30 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 32023 · 12021 · 17 dated
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
BoardEdmund Sullivan(Director)Vincent Grattan(Director)
Board seatChen Yu· per SEC Form D · $110.7M raise · filed Jan 2024
Co-investorsPontifax Venture CapitalTarnagulla VenturesVida Ventures
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)
BoardHelen S. Kim(Director)Oleg Nodelman(Director)inAndrew Levin(Director)
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundRA CapitalVida Ventures+2 more
CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
BiotechHealthtech
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalACORN BIOVENTURES+2 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesMPM BioImpactRoche Venture FundAgent Capital
Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.
BiotechHealthtech
Rand Sutherlandin
Co-investorsAccess BiotechnologyBain Capital Life SciencesDecheng CapitalOrbiMedSamsara BioCapitalVenrock Healthcare Capital Partners
San Diego, US
Board seatChen Yu· per SEC Form D · $200M raise · filed Aug 2023
Co-investorsAscenta CapitalLAVLilly Asia VenturesSilverArc Private
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
BiotechAustin, US
Alaa Halawa(Director)Jason Ehrlich(Executive Officer, Director)Jason Coloma(Director)
BoardTravis Murdoch(Director)Fred Cohen(Director)
Board seatCariad Chester· per SEC Form D · $330M raise · filed Jun 2026
Co-investorsMonograph Capital PartnersARCH Venture PartnersMC Healthcare Ventures
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoMichael Martin(President, Chief Executive Officer)Stephen Mullennix(Executive Officer)
BoardSerge Messerlian(Director)in
Board seatCariad Chester· per SEC Form D
Co-investorsCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesSoftBank Vision FundThe Column Group+1 more
ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes.
BiotechMedical Devices
Co-investorsOrbiMedVivo Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture Capital+2 more
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)Rick Modi(Chief Executive Officer, Board Member)
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)+1 more
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)
Co-investorsBain Capital Life SciencesSofinnova Ventures
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)
BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.Third Rock Ventures
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalThird Rock VenturesvenBio PartnersVida Ventures
Candid develops clear aligner technology and offers remote monitoring services for dental professionals to deliver orthodontic treatment.
ConsumerDigital HealthHealthtechMedical Devices
Nick Greenfield(Co-founder & CEO)in
Co-investorsA-Rod CorpAverin CapitalBessemer Venture PartnersBeyond CapitalF-Prime CapitalKube VC+2 more
Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations.
BiotechDigital HealthMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)Sherwin Sattarzadeh(Chief Operating Officer)Becker Hewes(Chief Medical Officer)
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)Jonathan Violin(President)
Co-investorsSanofi VenturesVenrockWellington Management
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)Tom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)Parameswaran Hari(Chief Medical Officer)Julie Feder(Chief Financial Officer)Dana Alexander(Chief Technical Officer)
Co-investorsAtlas VentureVertex Ventures HC
Co-investorsAndreessen HorowitzMonograph Capital Partners
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureBiotechnology Value FundForbionLightspeed Venture PartnersResearch Corporation Technologies
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesvenBio PartnersVersant VenturesVivo Capital+1 more
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalDeerfield Management Company+2 more
Carmot Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for obesity and type 2 diabetes, including injectable GLP-1/GIP receptor agonists (CT-388, CT-868) and an oral small molecule GLP-1 receptor agonist (CT-996).
BiotechDeep TechDigital Health
Co-investorsHorizons VenturesThe Column Group
Co-investorsEcoR1 CapitalHorizons VenturesLux CapitalThe Column GroupInnovation Endeavors
Co-investorsAvoro Capital AdvisorsLongitude CapitalScion Life SciencesVivo Capital
AI & Machine LearningBiotechHealthtech
Co-investorsAvoro Capital AdvisorsMedicxiUniQuest Extension Fund (UEF)venBio Partners
Co-investorsPfizer Venture InvestmentsM Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
IPOs and acquisitions across the tracked portfolioLB PharmaceuticalsNASDAQ: LBRXAktis OncologyNASDAQ: AKTSCG OncologyNASDAQ: CGONEntrada Therapeutics, Inc.NASDAQ: TRDAUpstream BioNASDAQ: UPBVicebioacq. by Sanofi
Portfolio news
latest coverage across their companiesCG Oncology · investing.com · Aug 19, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Adcendo ApS · geekwire.com · Jul 13, 2026
Candid Therapeutics · biopharmadive.com · Jul 6, 2026
Ollin Biosciences, Inc. · finsmes.com · Jun 24, 2026
Arbor Biotechnologies · altss.com · Jun 3, 2026
Fund performance · per public LP disclosures
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| TCG Crossover FundLPs: Employees' Retirement System of Rhode Island | 2021 | — | 16.4% | 1.42x | 0.71x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ6 insider ownership filings (Forms 3/4/5)
at Vor Biopharma Inc. (VOR), Surrozen, Inc./DE (SRZN)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has TCG Crossover made?
- TCG Crossover has 26 tracked investments, 1 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does TCG Crossover invest at?
- TCG Crossover invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does TCG Crossover focus on?
- TCG Crossover focuses on Biotech, Healthtech.
- Where is TCG Crossover located?
- TCG Crossover is headquartered in Palo Alto, US.
- Who does TCG Crossover co-invest with?
- TCG Crossover most often shares deals with OrbiMed, RA Capital, The Column Group, among 48 tracked co-investors.
Similar investors
Legendary Ventures is a venture capital firm focused on consumer, retail, and technology (CRT) companies, combining the expertise of venture capitalists and retail executives to support portfolio companies and identify acquisition partners.
Speedinvest operates a Portfolio Success program that connects its 400+ portfolio startups with customers, follow-on investors, industry experts, talent, discounted tools, and fellow founders across Europe, the Middle East, Africa, and beyond.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.
New Science Ventures (NSV) is a venture capital firm based in Connecticut and London that backs companies applying novel scientific approaches in the life sciences and information technology sectors.